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Introduction
Th e inert or noble gases helium, neon, argon, krypton 
and xenon exist as monatomic gases with low chemical 
reactivity. Considerable attention has focused on the use 
of xenon as a general anesthetic [1-4] and its potential for 
use as a neuroprotectant [5-7].
A number of recent studies report that helium may 
have neuroprotectant and/or cardioprotecant properties 
[8-13]. Argon also appears to be neuroprotective in certain 
in vitro and in vivo models [14,15]. At ﬁ rst sight it might 
appear unlikely that inert gases would have any biological 
activity. Nevertheless, evidence for the biological eﬀ ects 
of inert gases emerged from research into the physio-
logical eﬀ ects of diving. As long ago as the 1930s, 
nitrogen was shown to be the cause of the narcosis 
experi enced by divers [16,17]. Th e narcotic eﬀ ects of 
nitrogen begin to occur at a depth of about 30 meters (a 
pressure of ~3 atm), and increased with depth, with loss 
of consciousness occurring at depths of about 100 meters 
[18,19]. Behnke and Yarbrough showed in 1938 that if 
helium replaced nitrogen in the breathing mixture, the 
nitrogen narcosis was avoided [20]. Neon is also devoid 
of narcotic eﬀ ect [18]. Th e lighter inert gases helium and 
neon therefore appear both chemically and biologically 
inactive, at least at tolerable pressures (see below). Argon 
and krypton, on the other hand, induce narcosis more 
potently than nitrogen [17,21] – with the pressures resulting 
in anesthesia being 15.2 atm and 4.5 atm, respectively [22]. 
Th ese heavier inert gases therefore do have biological 
activity, at least under hyperbaric conditions.
Xenon was predicted to be an anesthetic at atmospheric 
pressure, based on its relative solubility in fat compared 
with argon, krypton and nitrogen. An eﬀ ect of xenon in 
animals was ﬁ rst shown by Lawrence and colleagues in 
1946, who reported sedation, ataxia and other behavioral 
eﬀ ects in mice exposed to between 0.40 and 0.78  atm 
xenon [21]. Th e anesthetic potency of inert gases follows 
the Meyer–Overton correlation with solubility in oil or 
fat (see Figure  1 and Table  1), with xenon being most 
potent (and most soluble in oil) followed by krypton and 
argon. Radon is the heaviest of the inert gases and might 
be predicted to be an anesthetic. Radon is radioactive, 
how ever, and exposure to radon – even at very low levels – 
is a health risk [23].
Th e lighter inert gases neon and helium are not 
anesthetics [24,25], at least up to the highest pressures 
(~100 atm) that can be tolerated before the confounding 
eﬀ ects of high-pressure neurological syndrome become 
pronounced. At these high pressures, the manifestations 
of high-pressure nervous syndrome include hyper excita-
bility, tremors and convulsions [26,27], which would act 
to oppose any sedative or anesthetic eﬀ ect. Th e lack of 
observable anesthetic eﬀ ects of helium and neon are 
either due to a lack of biological activity or, alternatively, 
these gases could have some intrinsic anesthetic potency 
at high pressures that is counteracted by the eﬀ ects of 
high-pressure nervous syndrome. If we make the 
assumption that these gases do have some intrinsic 
potency that would be observable in the absence of the 
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confounding eﬀ ects of high-pressure nervous syndrome, 
it is possible to calculate a theoretical anesthetic pressure. 
Based on the Meyer–Overton correlation and using loss 
of righting reﬂ ex in mice as the anesthetic endpoint, the 
predicted anesthetic pressures are 156 atm for neon and 
189 atm for helium (see Figure 1).
Pharmacology of xenon
Although the general anesthetic properties of xenon have 
been known since the 1950s, only recently have 
mole cular targets for xenon been identiﬁ ed that could 
mediate xenon’s biological actions. Th e ﬁ rst target to be 
identiﬁ ed was the N-methyl-d-aspartate (NMDA) 
receptor when, in 1998, it was shown that xenon 
inhibited NMDA-evoked currents in cultured hippo-
campal neurons by ~60% at a clinically relevant concen-
tration of 80% xenon [28]. Xenon was also found to 
inhibit NMDA receptors at glutamatergic hippocampal 
synapses by ~60%, but to have little eﬀ ect on synaptic α-
amino-3-hydroxy-5-methyl-4-isoxazole pro pi onic acid 
(AMPA)/kainate receptors [28]. Th e speci ﬁ city of xenon 
for the NMDA-mediated component of the glutamatergic 
synaptic response, together with the lack of eﬀ ect at 
inhibitory γ-amino-butyric acid (GABA)ergic synapses 
[28,29], imply that xenon acts post synaptically.
Another ﬁ nding consistent with a postsynaptic site of 
action for xenon is the lack of eﬀ ect of xenon on N-type 
voltage-gated calcium channels, which are involved in 
neurotransmitter release at neuronal synapses [30]. Th e 
molecular mechanism by which xenon inhibits the 
NMDA receptor has now been elucidated [31]. It has 
been shown that xenon competes for the binding of the 
co-agonist glycine at the glycine site on the NMDA 
receptor (Figure  2a). Based on protein crystallographic 
data, the binding of glycine is proposed to result in 
domain closure of the NMDA receptor leading to channel 
opening, and competitive inhibitors are suggested to 
prevent this domain closure [32]. Xenon therefore 
possibly stabilizes the open conformation of the domains, 
thus preventing channel opening.
Interestingly, recent crystallographic data on the bind-
ing of xenon to the Annexin V protein suggest that xenon 
may disrupt conformational changes in this protein [33]. 
Consistent with competitive inhibition at the NMDA-
receptor glycine site, xenon inhibits the NMDA receptor 
more potently at low glycine concentrations than at high 
glycine concentration (Figure 2b). In addition to competi-
tive inhibition at the glycine site, a Lineweaver–Burk 
Figure 1. Meyer–Overton correlation for the inert gases and 
nitrogen. Values of the Bunsen oil/gas partition coeffi  cient and the 
pressures for loss of righting refl ex in mice are taken from Table 1. The 
line shown is a least-squares regression of the data shown in the fi lled 
symbols. The points shown for neon and helium (open symbols) are 
theoretical predictions based on their oil/gas partition coeffi  cients. 
The theoretical pressures for anesthesia are 156 atm for neon and 
189 atm for helium.
Table 1. Physical properties of the inert gases and nitrogen
Physical property Helium Neon Nitrogen Argon Krypton Xenon
Atomic number 2 10 7 18 36 54
Atomic mass (g/mol)a 4.0 20.2 14.0 39.9 83.8 131.3
Density (g/l) (0°C)a 0.1785 0.900 1.251 1.784 3.736 5.887
Thermal conductivity (W/m/K) (300 K)b 0.1499a 0.0491 0.0260a 0.0178 0.0094 0.0056
Polarizability α (Å3)c 0.21 0.39 1.74 1.64 2.48 4.04
Water/gas partition coeffi  cient at 25°Cd 0.0085 0.010 0.015 0.031 0.053 0.095
Oil/gas partition coeffi  cient at 25°Cd 0.016 0.019 0.07 0.14 0.44 1.9
General anesthesia (atm)d Not anesthetic Not anesthetic 39 15.2 4.5 0.95 (mouse), 
      0.6 to 0.7 (human)
Partition coeffi  cients are experimentally measured Bunsen coeffi  cients. Anesthetic potency data for nitrogen, argon and krypton are for loss of righting refl ex in mice. For 
xenon, values are given for loss of righting refl ex in mice and general anesthesia minimum alveolar concentration in humans (see text for minimum alveolar concentration 
values). Data compiled from the following sources: aCRC Handbook of Chemistry & Physics [107]. bSelovar [108]. cTrudell and colleagues [106]. dRoth and Miller [109].
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analy sis (Figure 2b) shows that xenon has an additional 
noncompetitive component of inhibition [31]. It is possi-
ble that xenon’s mixed competitive and noncom peti tive 
inhibition underlies its beneﬁ cial proﬁ le compared with 
other NMDA receptor antagonists.
It was recently reported that xenon inhibits synaptic 
AMPA receptors in brain slices from the prefrontal 
cortex and spinal cord to a similar degree as NMDA 
recep tors [34] – in contrast to previous studies that found 
little or no inhibition of AMPA-mediated synaptic 
responses in hippocampal neurons [28,29]. Th e extent to 
which AMPA receptors are inhibited by xenon remains 
to be clariﬁ ed. If xenon does inhibit AMPA receptors, 
how ever, this inhibition could contribute to xenon 
anesthesia and neuroprotection.
Unlike most general anesthetics (for example, iso ﬂ urane, 
sevoﬂ urane, propofol, etomidate), xenon has little or no 
eﬀ ect on GABAA receptors. In cultured hippo campal 
neurons and mouse ﬁ broblast cells stably expres sing α1β1γ2L 
subunits, xenon has no eﬀ ect on currents elicited by 
exogenous GABA [28]. Similarly, xenon has no eﬀ ect on 
GABAergic synapses in cultured hippocampal neurons [29]. 
A study using Xenopus oocytes expressing α1β2γ2S subunits, 
however, reported a small (~15%) poten tiation of GABA-
evoked currents by xenon [35]. Whether this reﬂ ects 
diﬀ erences between Xenopus oocytes and mammalian 
systems or between diﬀ erent GABAA-recep tor subunit 
combinations is not clear. Nevertheless, xenon’s eﬀ ect on 
GABAA receptors is minimal compared with other 
anesthetics that typically potentiate GABAergic currents by 
100% or more at clinical concentrations [29,36-39].
Th e identiﬁ cation of xenon as an inhibitor of the 
NMDA receptor provided the ﬁ rst putative target for 
xenon anesthesia and prompted the idea that xenon 
might be neuroprotective (as glutamate excitotoxicity is 
involved in pathological conditions such as ischemia and 
traumatic brain injury [40,41]). Since then a small 
number of other targets have been identiﬁ ed that may 
also play a role in mediating xenon’s anesthetic and 
neuroprotective properties.
Th e two-pore domain potassium channel TREK-1 is 
activated by xenon [42] (Figure  2c). Two-pore domain 
Figure 2. Identifi ed targets for xenon that may mediate xenon anesthesia and neuroprotection. (a) Xenon binds to the N-methyl-D-aspartate 
(NMDA) receptor at its glycine binding site. (b) Lineweaver–Burk plot showing competitive inhibition of the NMDA receptor by xenon. Inhibition 
is glycine dependent, with greater inhibition at low glycine concentration (1 μM) (inset upper right) compared with high glycine concentration 
(100 μM) (inset lower left). (c) The two-pore domain potassium channel TREK-1 is activated by xenon in a concentration-dependent manner. Inset: 
the current activated by 80% xenon. Horizontal bar, 2-minute application of xenon, the current amplitude is 106 pA. (d) The ATP-sensitive potassium 
(KATP) channel is activated by xenon. Main fi gure shows that 80% xenon activates KATP and that the current is abolished by 0.1 mM of the specifi c 
blocker tolbutamide (Tb). Inset: percentage activation of the current measured at –20 mV by 50% and 80% xenon. *P <0.05. Figures adapted from: 
(a), (b) Dickinson and colleagues [31], (c) Gruss and colleagues [42], and (d) Bantel and colleagues [45].
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potassium channels modulate neuronal excitability by 
providing a background or leak potassium conduc tance. 
Activation of two-pore domain potassium channels will 
tend to hyperpolarize the cell membrane and reduce 
neuronal excitability. Volatile anesthetics such as 
halothane and iso ﬂ urane also activate TREK-1 [43]. 
Studies using TREK-1 knockout animals have implicated 
this channel in general anesthesia with volatile 
anesthetics, and in neuro protection by the fatty acid 
linolenate [44]. Whether activation of TREK-1 plays a 
role in mediating anesthesia and neuroprotection with 
xenon remains to be determined. Nevertheless, TREK-1 
is a plausible target for these actions of xenon.
Recently, xenon has been shown to activate another 
potassium channel, the plasmalemmal ATP-sensitive 
potas sium (KATP) channel [45]. KATP channels are inhibited 
by physiological levels of ATP and act as sensors of 
metabolic activity. In neurons, KATP channels are activated 
under conditions of physiological stress such as hypoxia. 
Activation of KATP channels reduces neuronal excitability 
and is protective against ischemic injury [46]. Clinical 
concentrations of xenon activate KATP channels by up to 
50% (Figure  2d), and this activation may mediate xenon 
preconditioning against ischemic injury [45].
Other ion channels that appear to be sensitive to xenon 
are neuronal nicotinic acetylcholine (nACh) receptors 
and 5-hydroxytryptamine type 3 (5-HT3) receptors. 
Neuronal nACh receptors, composed of α4β2 subunits, 
and homomeric α7 subunits are inhibited by xenon, 
where as α4β4-containing receptors are insensitive to 
xenon [36,47]. Although nACh receptors are inhibited by 
a number of anesthetics at clinically relevant concen-
trations, it is unclear whether this inhibition has any role 
in mediating general anesthesia. Neuronal nACh recep-
tors have been implicated in neuroprotection (for a 
review see [48]). However, it is activation of nACh recep-
tors that is neuroprotective. Hence, inhibition of nACh 
receptors by xenon is unlikely to play any role in xenon 
neuroprotection. Xenon inhibits human 5-HT3 receptors 
expressed in Xenopus oocytes by ~65% at clinical concen-
trations [49]. Th e clinical signiﬁ cance of this observation, 
however, is unclear. While 5-HT3 antagonists, such as 
ondansetron, are used as antiemetics, xenon appears if 
anything to cause more postoperative nausea and vomit-
ing compared with propofol [50].
Clinical use of xenon
Xenon was ﬁ rst used as a general anesthetic in the 1950s 
by Cullen and coworkers in the United States. Th ey 
reported successful anesthesia in two patients using 80% 
xenon, 20% oxygen. One patient was an 81-year-old male 
undergoing orchidectomy, and the other was a 38-year-
old female undergoing ligation of the fallopian tubes [51]. 
Th is was followed by use in a further ﬁ ve patients 
under going hernioplasty [52]. Loss of consciousness 
occurred when patients breathed 50% xenon, and a xenon 
concen tration of 75 to 80% was used for maintenance of 
anesthesia during the surgery. Following the deﬁ nition of 
minimum alveolar concentration as the standard anes-
thetic endpoint by Eger and colleagues [53], the value for 
xenon was determined. In a study of 28 patients, the 
minimum alveolar concentration of xenon was found to 
be 71% [54]. More recent estimates of the xenon 
minimum alveolar concen tration are in the range 63 to 
68% [55,56]. For the next two decades the use of xenon as 
a general anesthetic remained a curiosity and received 
little attention.
In the 1990s interest in xenon anesthesia received new 
impetus as xenon’s beneﬁ cial clinical properties were 
further investigated. Lachmann and coworkers found 
that xenon anesthesia resulted in greater hemodynamic 
stability compared with nitrous oxide [57,58]. Th e same 
studies showed xenon to be a profound analgesic, as 
evidenced by a greatly reduced need for fentanyl anal gesia 
during surgery. On average, patients receiving xenon 
needed only 20% of the dose of fentanyl required when 
nitrous oxide was used instead of xenon [57]. Similar 
ﬁ ndings were later reported by Nakata and colleagues 
[59]. A multi-modal experimental pain study in healthy 
volunteers reported that the analgesic potency of xenon 
was 1.5 times that of nitrous oxide [60]. Emergence from 
xenon anesthesia is rapid, with xenon emergence times 
being only 50% of the emergence times using nitrous 
oxide/sevoﬂ urane anesthesia, and the emergence times 
with xenon are independent of the duration of anesthesia 
[61,62]. Th ese properties of rapid induction and 
emergence arise from xenon’s very low blood/gas 
partition coeﬃ  cient of 0.115 [63] and its low solubility in 
lipids (xenon has an oil/gas partition coeﬃ  cient of 1.9; 
Table 1) compared with other inhala tional agents. For 
example, isoﬂ urane has a blood/gas coeﬃ  cient of 1.4 and 
an oil/gas partition coeﬃ  cient of 97, and for sevoﬂ urane 
these values are 0.69 and 53, respectively [64]. 
Xenon’s properties of cardiovascular stability, rapid 
onset and emergence from anesthesia, profound anal gesia 
and the fact that xenon is not metabolized are some of 
the characteristics of an ideal anesthetic. Xenon would be 
a useful replacement for nitrous oxide, with the 
advantage that xenon – being a natural component of the 
atmosphere – is not a greenhouse gas. Nitrous oxide, on 
the contrary, is chemically synthesized and is 230 times 
more potent as a greenhouse gas than carbon dioxide 
[65]. Furthermore, there are concerns regarding the 
possible toxic eﬀ ects of nitrous oxide, particularly in 
pediatric anesthesia (for reviews see [66,67]).
Th e discovery that xenon is an NMDA-receptor 
antago nist [28] led to the idea that xenon may be neuro-
protective. Th e renewed clinical interest in xenon in the 
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past 10 years is due, in large part, to xenon’s potential as a 
neuroprotectant. In 2003 the ﬁ rst multicenter random-
ized control trial, involving 224 patients in six centers, 
compared xenon/oxygen with isoﬂ urane/nitrous oxide 
anesthesia, and concluded that xenon anesthesia is as 
safe and eﬀ ective as the isoﬂ urane/nitrous oxide regimen, 
with the advantage that xenon exhibited more rapid 
recovery [68]. Another study of 20 patients undergoing 
coronary artery bypass surgery compared the cardio-
vascular eﬀ ects of xenon with nitrous oxide when used to 
supplement fentanyl-midazolam anesthesia. Th is study 
found that xenon provided better hemodynamic stability 
and preserved left ventricular function better compared 
with fentanyl-midazolam alone [3].
Studies in both cardiac and noncardiac patients showed 
that xenon does not impair cardiovascular function and 
maintains higher arterial pressure compared with propo-
fol [69-71]. A recent multicenter trial of xenon compared 
with isoﬂ urane found that xenon did not impair left 
ventricular function while isoﬂ urane signiﬁ cantly 
decreased global hemodynamic parameters [2].
Th ese clinical data show that xenon is safe and eﬀ ective 
as an anesthetic, with some advantages compared with 
conventional anesthesia regimens. Th e high cost of xenon 
and the need for closed-circuit anesthesia with a special-
ized anesthesia machine, however, will limit xenon’s 
widespread use unless a signiﬁ cant clinical beneﬁ t (for 
example, neuroprotection) can be found.
Xenon neuroprotection
Overactivation of glutamate receptors is involved in a 
number of pathological processes. Excessive entry of 
calcium, mediated by NMDA receptors, triggers bio-
chemical cascades that ultimately lead to neuronal cell 
death. Th is neurotoxicity due to overactivation of NMDA 
receptors was termed excitotoxicity by Olney [72], and is 
believed to underlie the neuronal injury observed in 
pathological conditions such as stroke and traumatic 
brain injury. Th ere has, for some time, been evidence that 
NMDA-receptor antagonists are neuroprotective in in 
vitro and in vivo brain injury models [40].
Following the discovery that xenon inhibits NMDA 
receptors, it was shown that xenon could protect 
neuronal cell cultures against injury induced by NMDA, 
glutamate or oxygen-glucose deprivation [6]. Th e same 
study showed xenon to be neuroprotective in vivo against 
neuronal injury caused by subcutaneous injection of N-
methyl(d,l)-aspartate in rats. Other NMDA-receptor 
antagonists such as nitrous oxide, ketamine and dizocil-
pine (MK801) have intrinsic neurotoxicity, but xenon 
appears devoid of neurotoxic eﬀ ects [73,74]. Xenon has 
now been shown to aﬀ ord neuroprotection in a variety of 
mammalian in vitro and in vivo models, including focal 
cerebral ischemia (mouse), neonatal asphyxia (mouse), 
neurocognitive deﬁ cit following cardiopulmonary bypass 
(rat and pig) and traumatic brain injury (mouse) [5,75-81] 
(Figure 3).
Inhibition of the NMDA receptor by xenon is plausible 
as a mechanism for xenon neuroprotection. Only very 
recently, however, has a direct connection between 
NMDA-receptor antagonism and xenon neuroprotection 
been demonstrated. Banks and colleagues [7] showed 
that acute xenon neuroprotection in an in vitro model of 
hypoxia/ischemia can be reversed by elevating the glycine 
concentration (Figure 4a), consistent with xenon neuro-
protection being mediated by inhibition of the NMDA 
receptor at its glycine site [31]. Interestingly, xenon 
appears to act syner gistically with the neuroprotective 
eﬀ ects of both hypothermia and the volatile anesthetic 
isoﬂ urane [76,82]. Although a mechanistic explanation 
for this syner gism remains to be determined, isoﬂ urane – 
in addition to its well-known actions at the GABAA 
receptor – also competes for glycine at the NMDA-
receptor glycine site [31]. Th e binding of volatile general 
anesthetics to proteins increases at lower temperatures 
due to favorable enthalpic interactions, and this increase 
in binding correlates with the increase in general 
anesthetic potency observed at lower temperatures [83-
85]. Whether xenon exhibits similar temperature 
dependence in its interactions with the targets mediating 
its anesthetic and neuroprotective eﬀ ects remains to be 
elucidated.
In addition to its action as an acute neuroprotectant 
(when applied during or after the insult), xenon is 
neuroprotective in preconditioning paradigms. Precon-
dition ing refers to the situation where a neuroprotectant 
is present before the insult, but not during or after the 
insult. Exposure to xenon for 2 hours, prior to hypoxia/
ischemia 24 hours later, was shown to result in reduction 
of injury in cultured neurons and in vivo in neonatal rats 
[45,86]. Inhibition of the NMDA receptor might be 
thought to be less likely to play any role in xenon 
preconditioning, as pathological glutamate release occurs 
only during and after the insult. Since NMDA receptors 
are not overstimulated before the insult, how their inhibi-
tion by xenon could mediate xenon preconditioning is 
not as clear as in the case of acute xenon neuroprotection. 
Nevertheless, NMDA receptors are known to couple to 
many intra cellular signaling pathways, so it remains 
possible that xenon inhibition of normal NMDA-receptor 
functioning before the insult could trigger some long-
term eﬀ ect that might mediate preconditioning.
Whether the NMDA receptor plays a role in xenon 
preconditioning remains to be determined. A recent 
study, however, has identiﬁ ed the ATP-sensitive potas-
sium KATP channel as being involved in xenon precon-
ditioning. Bantel and colleagues showed that xenon 
preconditioning against hypoxia/ischemia is abolished by 
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the plasmalemmal KATP channel blocker tolbutamide (see 
Figure 4b) [45], implying a role for the activation of the 
KATP channel. Th e mechanism by which transient activa-
tion of the KATP channel by xenon results in neuro-
protection 24 hours later is not known. Th ere is some 
evidence to suggest that xenon preconditioning results in 
an increase in phosphorylated cAMP response element 
binding protein and the pro-survival proteins B-cell 
lymphoma 2 and brain-derived neurotrophic factor [86], 
although a causal link with KATP channels has not been 
established.
Th e clinical trials discussed previously have looked at 
the safety and eﬃ  cacy of xenon as an anesthetic. Very few 
trials, however, have as yet directly addressed xenon 
neuro protection. Clinical trials are underway, or planned, 
looking speciﬁ cally at xenon as a neuroprotectant in 
cardiopulmonary bypass (a procedure associated with 
postoperative cognitive deﬁ cit), neonatal asphyxia and 
neurological deﬁ cit following cardiac arrest and resusci-
tation. To date, however, none of these trials have been 
completed.
A phase 1 trial in patients undergoing coronary artery 
graft on cardiopulmonary bypass that showed xenon can 
be safely delivered to these patients has been completed 
[1]. Two trials have examined postoperative cognitive 
deﬁ cit (POCD) in elderly patients undergoing noncardiac 
elective surgery, comparing xenon anesthesia with 
propofol anesthesia [87,88]. Neither study found a 
decreased incidence of POCD in the xenon group 
compared with the propofol group. Another study 
looking at POCD in elderly patients undergoing elective 
surgery found no advantage of xenon compared with 
desﬂ urane anesthesia [89].
Th e lack of eﬃ  cacy in these trials may, partly, be 
explained by the low numbers of patients resulting in 
underpowered studies. Only one of the studies involved 
Figure 3. Xenon is neuroprotective in a variety of mammalian in vitro and in vivo models. (a) Xenon treatment after cardiopulmonary 
resuscitation reduces neurological defi cit in a pig model. There is a signifi cant improvement in the neurological defi cit score (NDS) in xenon-
treated animals. †P <0.01, *P <0.05. (b) Xenon reduces infarct volume after focal ischemia in mice. Infarct volume after transient middle cerebral 
artery occlusion is signifi cantly reduced in xenon-treated animals compared with those treated with nitrous oxide. NS, not signifi cant. (c) Xenon 
improves neurological function following cardiopulmonary bypass (CPB) in a rat model. Xenon-treated animals received 60% xenon during CPB 
procedure. *P <0.05, **P <0.01, ***P <0.001. (d) Xenon is neuroprotective in an in vitro model of traumatic brain injury. Xenon (75%) give signifi cant 
neuroprotection (P <0.05) when applied immediately after the trauma (grey bars) or after a delay of 2 or 3 hours (white bars). Xenon is particularly 
eff ective at reducing the secondary injury that develops in the 72 hours following injury. Figures adapted from: (a) Fries and colleagues [78], (b) 
Homi and colleagues [5], (c) Ma and colleagues [75], and (d) Coburn and colleagues [77].
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more than 100 patients [87], and the other two used 
fewer than 40 patients each. Another confounding factor 
is that, although POCD is a recognized phenomenon, 
particularly in the older person, it is not straightforward 
to quantify POCD. Th e diﬀ erent studies used diﬀ erent 
assessment criteria and diﬀ erent times after surgery 
when assessments were performed. Larger trials will be 
required to deﬁ nitively determine whether xenon reduces 
POCD in elderly patients.
POCD following cardiopulmonary bypass (CPB) is 
thought to result in part from particulate and gaseous 
cerebral emboli subsequent to CPB. Concerns have been 
raised about the potential eﬀ ects of xenon on gas-
embolism growth as xenon may increase the size of pre-
existing gas emboli, but estimates as to the extent of this 
eﬀ ect vary widely in the literature. A theoretical study 
predicted rapid and inﬁ nite expansion of 50 nl air bubbles 
in the presence of 70% xenon [90]. An experimental 
study, however, found 50% xenon to have only a relatively 
modest eﬀ ect [91]. Both this study and other 
experimental studies have compared xenon with nitrous 
oxide, and show that xenon causes much less expansion 
of gas bubbles than does nitrous oxide [91-93].
Studies in animal models of CPB have reported diﬀ er-
ing results regarding the eﬀ ects of xenon on gas emboli. 
Grocott and colleagues reported a modest (17%) increase 
in the size of large (~400  nl) air bubbles artiﬁ cially 
introduced into a bypass circuit in a rat model in the 
presence of 70% xenon [93]. Another study using a rat 
CPB model combined with artiﬁ cially introduced air 
bubbles of 300 nl reported that exposure to 56% xenon 
resulted in increased infarct volume and neurological 
deﬁ cit compared with nitrogen [94]. A later study by the 
same group, however, concluded that xenon did not 
aﬀ ect neurological or histological outcome [95]. Th e 
reasons for these discrepancies are not clear.
It should be noted that the artiﬁ cial introduction of a 
small number of relatively large air bubbles into the CPB 
circuit does not accurately model the clinical scenario, 
where it is more likely that bubbles will be small in size 
but may be numerous. Th e only human trial that has 
directly measured embolic load in CPB patients during 
xenon treatment found that xenon (20 to 50%) caused no 
increase in embolic load [1]. Nevertheless, the issue of 
whether xenon may increase embolic load should be 
borne in mind (and monitored) in future clinical trials.
Aside from its potential to reduce POCD, xenon could 
be argued to be more likely to show a beneﬁ t in situations 
where the potential damage in the absence of any 
neuroprotection is more severe. In this regard it will be 
interesting to see whether clinical trials of xenon in 
neonatal asphyxia show xenon to be neuroprotective, as 
has been demon strated in in vivo models of neonatal 
asphyxia [76,96].
Figure 4. Diff erent targets mediate acute xenon 
neuroprotection and xenon preconditioning. (a) Acute xenon 
neuroprotection against hypoxia/ischemia involves the N-methyl-D-
aspartate-receptor glycine site. Acute xenon protection is reversed 
by adding glycine. Applying 50% atm xenon after hypoxia/ischemia 
in the absence of added glycine (black bars) gives robust protection 
(32 ± 6% of control injury). However, the protective eff ect of 50% 
atm xenon is abolished in the presence of 100 μM glycine. Addition 
of the inhibitory glycine receptor antagonist strychnine (100 nM) 
had no eff ect on control oxygen-glucose deprivation (OGD) with 
or without glycine, xenon neuroprotection without glycine, or 
the reversal of xenon neuroprotection by glycine. The error bars 
are standard errors from an average of 44 slices at each condition. 
Data have been normalized to the control OGD with no added 
glycine. *Value signifi cantly diff erent (P <0.05) from control OGD. 
n.s., not signifi cant. Figure adapted from Banks and colleagues [7]. 
(b) Xenon preconditioning against hypoxia/ischemia involves the 
plasmalemmal ATP-sensitive potassium (KATP) channel. Exposure of 
cultured neurons to 75% xenon for 2 hours protects cells against 
hypoxia/ischemia 24 hours later (white bar). This eff ect is abolished 
by the plasmalemmal KATP blocker tolbutamide (Tb) (0.1 mM) but 
not by the mitochondrial KATP channel blocker 5-hydroxy-decanoic 
acid (5-HD) (0.5 mM). *P <0.05, **P <0.01. Figure adapted from 
Bantel and colleagues [45].
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Use of helium and other inert gases as potential 
neuroprotectants
Th e evidence for the neuroprotective properties of xenon 
has prompted interest in investigating whether other 
inert gases have similar potential as neuroprotectants. 
Helium is the lightest of the inert gases, is not an 
anesthetic, is much more abundant and is signiﬁ cantly 
cheaper to produce than xenon. Mixtures of helium and 
oxygen (heliox) are used in diving to avoid the eﬀ ects of 
nitrogen narcosis. Medical use of helium/oxygen has 
been advocated in patients with respiratory illness. Th e 
ﬁ rst use of helium/oxygen in acute asthma patients was 
in 1934 [97], with the study reporting an alleviation of 
dyspnea. Recent systematic reviews, however, have 
concluded that the current evidence does not support 
use of helium/oxygen in acute asthma or chronic 
obstructive pulmonary disease [98,99], and helium has 
not been widely used to treat respiratory illness.
To date there have been relatively few studies investi-
gating the potential of helium as a neuroprotectant, and 
these have been limited to in vitro and in vivo models. In 
an in vitro organotypic hippocampal brain slice model of 
traumatic brain injury, mild hyperbaric helium (0.5 or 
1 atm) was found to be neuroprotective [77]. Th is study 
found that the outcome was signiﬁ cantly worse if 
nitrogen replaced helium. Th e authors concluded that the 
eﬀ ect of helium was the result of a beneﬁ cial eﬀ ect of 
pressure per se combined with an attenuation of the 
deleterious eﬀ ects of nitrogen [77]. Interestingly, an in 
vitro model of hypoxic/ischemic injury using the same 
organotypic brain slice preparation found no eﬀ ect of 
0.5 atm helium [7]. Th is may reﬂ ect the fact that diﬀ erent 
mechanisms of injury are activated in these diﬀ erent 
injury paradigms. Another in vitro study using cultured 
neurons reported that normobaric helium (75%) was 
actually detrimental to neuronal survival after hypoxia/
ischemia [15]. An in vivo study in rats subjected to focal 
ischemia, however, reported that 75% helium reduced the 
infarct volume and improved functional neurological 
outcome 24 hours after injury [11]. Th e reasons for the 
diﬀ ering ﬁ ndings with helium in these studies are not 
entirely clear.
Nevertheless, it is interesting to note that these variable 
eﬀ ects with helium contrast with the eﬀ ects observed 
with xenon, which appears to be neuroprotective in all of 
these models. While a number of pharmacological 
targets have been identiﬁ ed for xenon, no targets have 
been identiﬁ ed for helium.
Helium is considered to be inert and lacking in an 
intrinsic pharmacological eﬀ ect; helium is therefore often 
used as a pressurizing gas in studies of the biological 
eﬀ ects of pressure per se [100,101]. Compared with 
xenon, which has neuroprotective eﬀ ects at 
concentrations similar to those causing anesthesia, it 
seems implausible that the non anesthetic helium would 
have any pharmacological eﬀ ect at or near atmospheric 
pressure. Even if we assume, as predicted by the Meyer–
Overton correlation, that helium might be anesthetic at 
~200 atm (Figure 1), if helium was neuroprotective at 1 
atm it would be acting at 1/200th of its anesthetic 
concentration. Eﬀ ects at such low relative concentrations 
have not been observed for other anes thetic 
neuroprotectants. Even in the case of xenon, which is 
neuroprotectant at subanesthetic concentrations as low 
as ~20% [76], the ratio of neuroprotectant to anes thetic 
concentration is only ~1/3. Helium therefore seems 
unlikely to be acting via a pharmacological mecha nism.
An interesting recent study by David and colleagues, 
however, has identiﬁ ed a probable physical mechanism 
that may underlie the reported neuroprotective eﬀ ects of 
helium [12]. Th is study in rats found that, at room 
temperature, 75% helium resulted in signiﬁ cantly reduced 
brain infarct size and improved functional neurological 
outcome when helium treatment took place following 
middle cerebral artery occlusion. Th e authors discovered, 
however, that breathing helium gas below body 
temperature (for example, 25°C) caused hypothermia in 
the rats (Figure  5a). Helium was neuroprotective when 
the inspired temperature was 25°C, but the neuro-
protective eﬀ ect was abolished when the temperature of 
the inspired helium was increased to 33°C (abolishing the 
hypo thermia) (Figure 5b). Th e authors conclude that the 
neuroprotective eﬀ ects of helium are due to hypothermia.
Neuroprotection via cooling is well established in 
model systems and is used clinically (for reviews see 
[102,103]). Th e reason that helium causes hypothermia is 
due to its high thermal conductivity compared with air. 
Th e thermal conductivity of helium is 0.1499 W/m/K – 
almost six times greater than nitrogen, which has a 
thermal conductivity of 0.0260 W/m/K (Table 1). Breath-
ing helium at a temperature lower than body temperature 
will hence cause a reduction in core temperature. Th is 
phenomenon is recognized in divers breathing heliox 
mixtures who require heated diving suits and heated gas 
delivery equipment in order to avoid hypothermia. Xenon, 
on the contrary, has a thermal conductivity ﬁ ve times 
lower than nitrogen (see Table 1), and therefore would not 
result in cooling via this mechanism. In common with 
other anesthetics, however, xenon exhibits an anesthesia-
induced hypothermia. Th e neuroprotection observed with 
helium is probably therefore due to helium-induced 
hypothermia rather than to any pharmacological eﬀ ect of 
helium. Th e cooling eﬀ ect of helium could also occur in in 
vitro systems lacking adequate gas-tempera ture control, 
and this may explain the variable eﬀ ects observed in 
diﬀ erent studies using helium.
Th e other inert gases – neon, argon and krypton – have 
received very little attention as potential 
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neuroprotec tants. Argon and krypton are anesthetics 
under hyper baric conditions, at 15 atm and 4.5  atm, 
respectively, and might be expected to be neuroprotective 
at these pressures. It is conceivable that argon and 
krypton could be neuroprotective at atmospheric 
pressure – by analogy with xenon, which exhibits 
neuroprotective properties even at ~1/3 of its anesthetic 
potency. Neon, on the contrary, is not an anesthetic – but 
based on its oil solubility, neon might be predicted to be 
an anesthetic at ~160  atm. By the same argument as 
above for helium, neon is unlikely to have a 
pharmacological neuro protective eﬀ ect at atmos pheric 
pressures. Neon’s thermal conductivity is twice that of 
nitrogen, hence neon breath ing might induce 
hypothermia. Any eﬀ ect, how ever, is likely to be much 
less than that caused by helium.
Argon does appear to be neuroprotective in certain 
model systems. In an in vivo study, normobaric argon (25 
to 77%) increased survival rates of rats exposed to varying 
degrees of hypoxia [104]. An in vitro study using cochlear 
organotypic cultures from rats found that argon (74 to 
95%) was protective against hypoxic injury and injury 
induced by the anticancer drug cisplatin or the antibiotic 
gentamycin [14]. Another in vitro study using mouse 
cortical cell cultures found that 75% argon protected 
against hypoxic/ischemic injury but that the same 
concen trations of krypton or neon had no eﬀ ect [15]. A 
recent in vitro study has shown that normobaric argon 
protects mouse hippocampal organotypic cultures 
against both ischemic and traumatic injury [105]. Argon 
there fore does indeed appear to be neuroprotective at 
normo baric pressures. Th is eﬀ ect is most probably 
mediated by a pharma co logical mechanism. Th e thermal 
conductivity of argon is less than that of nitrogen – hence 
argon will not cause hypothermia via this physical 
mecha nism, but may cause anesthesia-induced hypo-
thermia at elevated pressures. Th e reason for the lack of 
neuroprotective eﬀ ect of krypton is unclear. To date, 
however, there has only been a single in vitro study on 
krypton.
Whether krypton has a neuroprotective eﬀ ect in other 
injury paradigms merits further investigation. No mole-
cu lar targets have as yet been identiﬁ ed that could 
mediate anesthesia or neuroprotection by argon or 
krypton. Molecular modeling, however, suggests that the 
inert gases with anesthetic properties (argon, krypton 
and xenon) and nitrogen all make similar types of inter-
actions with a model protein cavity [106]. Th e binding 
energies of the inert gases can only arise from favorable 
enthalpic (ΔH) contributions due to London Dispersion 
forces (also known as van der Waals interactions) and/or 
charge-induced dipole interactions. Both of these 
enthalpy terms are proportional to the polarizability (α) 
of the gas (Table  1). Relative to a particular standard 
state, the energy of these favorable enthalpic (ΔH) terms 
must be suﬃ  cient to overcome the unfavorable entropy 
term associated with binding. Th e anesthetic inert gases 
(argon, krypton and xenon) can be distinguished from 
the nonanesthetic helium and neon by their greater 
polariza bility [106] (Table  1), which results in larger 
favorable enthalpic interactions. Xenon, for example, has 
a value of α of 4.04 Å3, which is 19 times greater than that 
of helium (0.21 Å3) and 10 times that of neon (0.39 Å3). 
Argon and krypton have α values of 1.64 Å3 and 2.48 Å3, 
respectively, which are eight times and 12 times greater 
than the value for helium. Th erefore it is plausible that 
Figure 5. Helium causes hypothermia in rats, which mediates its neuroprotective eff ect. (a) Breathing 75% helium at temperatures lower 
than 37°C results in hypothermia. (b) Breathing 75% helium at 25°C following injury protects the cortex against focal ischemic injury (light grey bar). 
The protective eff ect of helium is abolished if the gas is warmed to 35°C (dark grey bars). The striatum is resistant to both injury and the protective 
eff ects of hypothermia (shown on the right). *P <0.05. Figures adapted from David and colleagues [12].
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argon and krypton interact with the same targets as 
xenon, even if somewhat more weakly. Th at anesthesia 
and neuroprotection by the inert gases share similar 
mechanisms is, therefore, an interesting possibility.
Conclusions
Th e present review summarizes studies on the 
pharmacology and clinical uses of the inert gases as 
anesthetics and neuroprotectants. Xenon is the only inert 
gas that is an anesthetic at atmospheric pressure. A 
relatively small number of pharmacological targets for 
xenon have been identiﬁ ed that may play a role in xenon 
anesthesia and neuroprotection; the NMDA receptor, the 
two-pore domain potassium channel TREK-1 and the 
KATP channel. Xenon has been shown to be an eﬀ ective 
neuroprotectant in in vitro and in vivo injury models, and 
the results of clinical trials to assess xenon’s eﬀ ectiveness 
as a neuroprotectant in patients are eagerly awaited. Th e 
mecha nisms involved in xenon neuroprotection are 
begin ning to be understood. Th ere is new evidence that 
inhibition of the NMDA receptor by xenon mediates 
acute xenon neuroprotection, and that the KATP channel is 
involved in xenon preconditioning.
Helium has been shown to be neuroprotective in vivo, 
but this eﬀ ect is mediated by helium-induced hypo ther-
mia rather than by a pharmacological eﬀ ect. Even if 
helium is devoid of pharmacological action, the cooling 
eﬀ ect resulting from helium’s high thermal conductivity 
could be exploited clinically. Furthermore, as xenon and 
hypothermia appear to act synergistically in experimental 
models, it is possible that the two neuroprotective 
strategies of xenon and hypothermia could be applied 
simultaneously using a helium/xenon mixture combined 
with an appropriate controlled gas-cooling apparatus.
Argon and krypton are anesthetic at elevated pressures, 
but few studies have investigated neuroprotection by 
argon and krypton. However, argon appears to be neuro-
protective at atmospheric pressure in certain model 
systems. Further studies are needed to determine whether 
argon and krypton have potential as neuroprotectants.
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